Across TCGA pan-cancer cohorts, IFT74 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IFT74 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher IFT74 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFT74 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
MESO, SKCM, and UCS are the cancer types where IFT74 Mutation most reproducibly stratifies survival.